Autolus Therapeutics (ADR) (AUTL)
Commercializes AUCATZYL while developing programmed T-cell therapies for cancer and autoimmune diseases.
$2.03
After hours−0.01 (−0.44%)
At close$2.04(+5.15%)
Something off on this page? Send us feedback.
Next report
Nov 11, 26
in 50 days
EPS estimate
−$0.20
Revenue estimate
$40.0M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.09−$0.26−$0.18−$0.30−$0.34−$0.27−$0.15Pending
Estimate−$0.21−$0.24−$0.24−$0.23−$0.26−$0.29−$0.21−$0.20
Surprise+57.1%−8.3%+25.0%−30.4%−30.8%+6.9%+28.6%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$29.0K$9.0M$20.9M$21.2M$24.3M$26.2M$45.7MPending
Estimate$1.5M$2.2M$21.1M$24.4M$23.9M$26.3M$38.6M$40.0M
Surprise−98.1%+309.1%−0.7%−13.2%+1.6%−0.2%+18.5%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | −$0.12 | — | — |
| Sep 2028 | −$0.14 | — | — |
| Jun 2028 | −$0.15 | — | — |
| Mar 2028 | −$0.15 | — | — |
| Dec 2027 | −$0.16 | — | — |
| Sep 2027 | −$0.16 | — | — |
| Jun 2027 | −$0.16 | — | — |
| Mar 2027 | −$0.16 | — | — |
| Dec 2026 | −$0.17 | — | — |
| Nov 2026 | −$0.20 | — | — |
| Aug 2026 | −$0.21 | −$0.15 | +28.6% |
| May 2026 | −$0.29 | −$0.27 | +6.9% |
| Mar 2026 | −$0.26 | −$0.34 | −30.8% |
| Nov 2025 | −$0.23 | −$0.30 | −30.4% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Sep 2018 | |||
| Mar 2018 | |||
| Jun 2018 | — | — | — |
| Sep 2017 | |||
| Jun 2017 | |||
| Mar 2017 | |||
| Dec 2016 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | −$0.12 | — | — | $76.8M | — | — | — |
| Sep 2028 | −$0.14 | — | — | $70.4M | — | — | — |
| Jun 2028 | −$0.15 | — | — | $65.2M | — | — | — |
| Mar 2028 | −$0.15 | — | — | $60.7M | — | — | — |
| Dec 2027 | −$0.16 | — | — | $49.4M | — | — | — |
| Sep 2027 | −$0.16 | — | — | $47.3M | — | — | — |
| Jun 2027 | −$0.16 | — | — | $44.1M | — | — | — |
| Mar 2027 | −$0.16 | — | — | $42.5M | — | — | — |
| Dec 2026 | −$0.17 | — | — | $38.4M | — | — | — |
| Nov 11, 2026 | −$0.20 | — | — | $40.0M | — | — | — |
| Aug 11, 2026 | −$0.21 | −$0.15 | +28.6% | $38.6M | $45.7M | +18.5% | +12.6% |
| May 14, 2026 | −$0.29 | −$0.27 | +6.9% | $26.3M | $26.2M | −0.2% | −7.0% |
| Mar 27, 2026 | −$0.26 | −$0.34 | −30.8% | $23.9M | $24.3M | +1.6% | −6.2% |
| Nov 12, 2025 | −$0.23 | −$0.30 | −30.4% | $24.4M | $21.2M | −13.2% | −9.3% |
| Aug 12, 2025 | |||||||
| May 8, 2025 | |||||||
| Mar 20, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 17, 2024 | |||||||
| Mar 14, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 4, 2023 | |||||||
| Mar 7, 2023 | |||||||
| Nov 3, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 5, 2022 | |||||||
| Mar 10, 2022 | |||||||
| Nov 3, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 6, 2021 | |||||||
| Mar 4, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 3, 2020 | |||||||
| Nov 7, 2019 | |||||||
| Aug 8, 2019 | |||||||
| May 14, 2019 | |||||||
| Feb 25, 2019 | |||||||
| Nov 23, 2018 | |||||||
| Sep 26, 2018 | |||||||
| Mar 31, 2018 | |||||||
| Jun 22, 2018 | — | — | — | — | — | — | — |
| Sep 30, 2017 | |||||||
| Jun 30, 2017 | |||||||
| Mar 31, 2017 | |||||||
| Dec 31, 2016 |